LifeMD (LFMD) Stock Forecast & Price Target

Compare

713 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LFMD Analyst Ratings

Strong Buy

6 Buy

1 Hold

0 Sell

Based on 7 analysts giving stock ratings to

LifeMD

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LFMD Stock 12 Month Forecast

Average Price Target

$9.67

▲(195.72% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for LifeMD in the last 3 months. The average price target is $9.67 with a high forecast of $15.00 and a low forecast of $6.00. The average price target represents a 195.72% change from the last price of $3.27.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","9":"$9","16":"$16","5.5":"$5.5","12.5":"$12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.5,9,12.5,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,4.449230769230769,5.328461538461538,6.207692307692307,7.086923076923076,7.966153846153846,8.845384615384615,9.724615384615385,10.603846153846154,11.483076923076924,12.362307692307693,13.241538461538463,14.12076923076923,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,4.039230769230769,4.508461538461538,4.977692307692307,5.446923076923077,5.916153846153846,6.3853846153846145,6.854615384615384,7.323846153846153,7.793076923076923,8.262307692307692,8.731538461538461,9.20076923076923,{"y":9.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,3.756923076923077,3.943846153846154,4.13076923076923,4.317692307692307,4.504615384615384,4.691538461538461,4.878461538461538,5.065384615384615,5.252307692307692,5.439230769230769,5.626153846153846,5.813076923076923,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.94,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.17,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$15.00

Average Price Target$9.67

Lowest Price Target$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yi Chen

H.C. Wainwright

Buy

175.23%

Upside

Reiterated

11/19/25

LifeMD's Strategic Positioning and Financial Health Reinforce Buy Rating Despite Revenue MissOur 12-month price target is derived from a comparable universe analysis. This employs a spectrum of telehealth and digital health product companies contributing to a number of comparative valuation metrics, including an EV/Revenue multiple.

Scott Schoenhaus

KeyBanc

―

Buy

―

Reiterated

11/19/25

Analysts Offer Insights on Healthcare Companies: LifeMD (NASDAQ: LFMD) and Medtronic (NYSE: MDT)

Steven Valiquette

Mizuho Securities

$8→$6

Hold

83.49%

Upside

Reiterated

11/18/25

LifeMD price target lowered to $6 from $8 at MizuhoLifeMD price target lowered to $6 from $8 at Mizuho

Ryan Meyers

Lake Street

Buy

144.65%

Upside

Reiterated

11/18/25

Lake Street Reaffirms Their Buy Rating on LifeMD (LFMD)

Unknown Analyst

B. Riley Securities

Not Ranked

B. Riley Securities

$12→$10

Buy

205.81%

Upside

Reiterated

11/18/25

B. Riley Securities Reaffirms Their Buy Rating on LifeMD (LFMD)Reiterate Buy rating while lowering our PT from $12 to $10.

Sarah James

Cantor Fitzgerald

$15

Buy

358.72%

Upside

Reiterated

11/17/25

Cantor Fitzgerald Remains a Buy on LifeMD (LFMD)

David Larsen

BTIG

$18→$10

Buy

205.81%

Upside

Reiterated

11/17/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NASDAQ: NRXP), LifeMD (NASDAQ: LFMD) and Hims & Hers Health (NYSE: HIMS)

Ilya Zubkov

Freedom Capital Markets

$12→$13

Buy

297.55%

Upside

Reiterated

03/18/25

LifeMD Inc (LFMD) PT Raised to $13 at Freedom BrokerFreedom Broker analyst Ilya Zubkov raised the price target on LifeMD Inc (NASDAQ: LFMD) to $13.00 (from $12.00) while maintaining a Buy rating

Alex Fuhrman

Lucid Capital

―

Buy

―

Reiterated

03/10/25

Craig-Hallum Sticks to Its Buy Rating for LifeMD (LFMD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yi Chen

H.C. Wainwright

Buy

175.23%

Upside

Reiterated

11/19/25

Scott Schoenhaus

KeyBanc

―

Buy

―

Reiterated

11/19/25

Analysts Offer Insights on Healthcare Companies: LifeMD (NASDAQ: LFMD) and Medtronic (NYSE: MDT)

Steven Valiquette

Mizuho Securities

$8→$6

Hold

83.49%

Upside

Reiterated

11/18/25

LifeMD price target lowered to $6 from $8 at MizuhoLifeMD price target lowered to $6 from $8 at Mizuho

Ryan Meyers

Lake Street

Buy

144.65%

Upside

Reiterated

11/18/25

Lake Street Reaffirms Their Buy Rating on LifeMD (LFMD)

Unknown Analyst

B. Riley Securities

Not Ranked

B. Riley Securities

$12→$10

Buy

205.81%

Upside

Reiterated

11/18/25

B. Riley Securities Reaffirms Their Buy Rating on LifeMD (LFMD)Reiterate Buy rating while lowering our PT from $12 to $10.

Sarah James

Cantor Fitzgerald

$15

Buy

358.72%

Upside

Reiterated

11/17/25

Cantor Fitzgerald Remains a Buy on LifeMD (LFMD)

David Larsen

BTIG

$18→$10

Buy

205.81%

Upside

Reiterated

11/17/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NASDAQ: NRXP), LifeMD (NASDAQ: LFMD) and Hims & Hers Health (NYSE: HIMS)

Ilya Zubkov

Freedom Capital Markets

$12→$13

Buy

297.55%

Upside

Reiterated

03/18/25

LifeMD Inc (LFMD) PT Raised to $13 at Freedom BrokerFreedom Broker analyst Ilya Zubkov raised the price target on LifeMD Inc (NASDAQ: LFMD) to $13.00 (from $12.00) while maintaining a Buy rating

Alex Fuhrman

Lucid Capital

―

Buy

―

Reiterated

03/10/25

Craig-Hallum Sticks to Its Buy Rating for LifeMD (LFMD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering LifeMD

1 Month

xxx

Success Rate

6/11 ratings generated profit

Average Return

+2.78%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +2.78% per trade.

3 Months

xxx

Success Rate

11/16 ratings generated profit

Average Return

+11.91%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +11.91% per trade.

1 Year

Alex FuhrmanLucid Capital

Success Rate

5/16 ratings generated profit

Average Return

-6.85%

reiterated a buy rating 9 months ago

Copying Alex Fuhrman's trades and holding each position for 1 Year would result in 31.25% of your transactions generating a profit, with an average return of -6.85% per trade.

2 Years

xxx

Success Rate

14/33 ratings generated profit

Average Return

+38.60%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 42.42% of your transactions generating a profit, with an average return of +38.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LFMD Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LFMD has received 8 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. LFMD average Analyst price target in the past 3 months is 9.67.

Each month's total comprises the sum of three months' worth of ratings.

LFMD Financial Forecast

LFMD Earnings Forecast

Next quarter’s earnings estimate for LFMD is -$0.06 with a range of -$0.14 to $0.10. The previous quarter’s EPS was -$0.10. LFMD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year LFMD has Performed in-line its overall industry.

LFMD Sales Forecast

Next quarter’s sales forecast for LFMD is $48.57M with a range of $45.00M to $58.00M. The previous quarter’s sales results were $60.17M. LFMD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year LFMD has Performed in-line its overall industry.

LFMD Stock Forecast FAQ

What is LFMD’s average 12-month price target, according to analysts?

Based on analyst ratings, LifeMD’s 12-month average price target is 9.67.

What is LFMD’s upside potential, based on the analysts’ average price target?

LifeMD has 195.72% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LFMD a Buy, Sell or Hold?

LifeMD has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.

What is LifeMD’s price target?

The average price target for LifeMD is 9.67. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $15.00 ,the lowest forecast is $6.00. The average price target represents 195.72% Increase from the current price of $3.27.

What do analysts say about LifeMD?

LifeMD’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of LFMD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

LifeMD (LFMD) Stock Forecast & Price Target

LFMD Analyst Ratings

LFMD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering LifeMD

LFMD Analyst Recommendation Trends

LFMD Financial Forecast

LFMD Earnings Forecast

LFMD Sales Forecast

LFMD Stock Forecast FAQ

Detailed List of Analyst Forecasts